The activation of nAChRs counteracts TNF-α-induced cutaneous inflammation by engaging the STAT3 and NF-κB signaling pathways, whereas treatment with an α7nAChR antagonist exacerbates psoriasis [4]. The gene discussed is NFKB1; the disease is psoriasis.